N-acetylglucosamine-1-phosphate transferase subunits alpha and betaGenealiases: GNPTA · ICD
Q-omics provides the consensus-scored GNPTAB profile across patient tissues and cancer cell-line models. GNPTAB expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, GNPTAB is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, GNPTAB RNA expression shows 20,434 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, COAD, and UVM as cancer lineages where GNPTAB shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GNPTAB — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GNPTAB survival associations across molecular data types. GNPTAB RNA expression shows survival associations in the most cancer types (23), followed by mutation status (7) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GNPTAB RNA expression–survival associations across cancer types. High GNPTAB expression shows unfavorable associations in MESO, UVM and LUSC, but favorable associations in KIRC, HNSC and CESC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for GNPTAB RNA expression.
This table summarizes GNPTAB tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 8. The strongest signals are observed in COAD for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for GNPTAB. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GNPTAB shows lower tumor expression in COAD and LUAD and higher tumor expression in KIRC, KIRP, HNSC and LIHC. The COAD box plot shows higher GNPTAB RNA expression in normal versus tumor tissue (log2 FC = −0.783, t-test p < 0.001).
This table shows molecular features associated with GNPTAB in patient tissues and cancer cell lines. In patient samples, GNPTAB shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, GNPTAB RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LARGE_INTESTINE.
